SCHEMBL20722137

SCHEMBL20722137

O=C(COC1CC(OC(F)(F)F)C1)NC12CC(NCC(=O)c3ccc(Cl)cc3F)(C1)C2

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 20/20 0.61
▸ KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23358955 0.91 ATF4 (0.58) ATF4KCNH2
SCHEMBL23358920 0.89 ATF4 (0.56) ATF4KCNH2
SCHEMBL23358842 0.86 ATF4 (0.62) ATF4KCNH2
SCHEMBL20722136 0.86 ATF4 (0.58) ATF4KCNH2
SCHEMBL20721953 0.84 ATF4 (0.59) ATF4KCNH2
SCHEMBL23358893 0.84 ATF4 (0.54) ATF4KCNH2
SCHEMBL20722115 0.84 ATF4 (0.71) ATF4KCNH2
SCHEMBL23358895 0.83 ATF4 (0.54) ATF4KCNH2
SCHEMBL23358997 0.81 ATF4 (0.57) ATF4KCNH2
SCHEMBL23359005 0.80 ATF4 (0.56) ATF4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. 2022-12-29 — — US disclosed
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2022-02-01 — — US disclosed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 — — US disclosed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 — — EP disclosed
WO-2019032743-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885KCNH2 4777/4885
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885KCNH2 4777/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 ATF4 183/4885KCNH2 4635/4885
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885KCNH2 4777/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E ATF4 81/4885KCNH2 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback